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Background:  We  have  reported  that   and   adrenergic  blockers  could  protect  against  emotional  stress-
induced cardiac  dysfunction.  Azelnidipine  is a unique  calcium  blocker  which  does  not  increase  heart
rate.  The  purpose  of  this  study  is to evaluate  the  effect  of  azelnidipine  to prevent  stress-induced  cardiac
dysfunction.
Methods  and  results:  Rats  premedicated  with  azelnidipine  (0.3 mg/kg),  labetalol  (3 mg/kg),  or  vehicle,
were  restrained  for 30 min  (immobilization  stress:  IMO) to reproduce  emotional  stress,  and  anesthetized
to release  stress.  We measured  the  fractional  area  change  (FAC)  by  echocardiography,  blood  pressure,  and
heart  rate  at  the  end  of  IMO  and  every  10 min  for 60 min  after  IMO.  During  IMO,  FAC in the  labetalol  group
was signiﬁcantly  lower  than  that  in  the other  two  groups.  At  20 min  after  IMO,  FAC  in the  azelnidipinealcium blocker
· adrenergic blockers
or  labetalol  group  was  signiﬁcantly  higher  than that  in  the  vehicle  group  (86  ±  9%, 73 ±  5%  vs.  56  ± 11%,
p  <  0.05).  During  IMO, mean  blood  pressure  in the  azelnidipine  or  labetalol  group  was  signiﬁcantly  lower
than  that  in  the  vehicle  group  (107  ± 5 mmHg,  106  ±  17 mmHg  vs.  124  ± 5 mmHg,  p  < 0.05).
Conclusion:  Acute  administration  of azelnidipine  could  prevent  a sudden  drop  of cardiac  function  after
acute  stress  like  IMO.  Azelnidipine  might  have  a protective  effect  on  stress-induced  cardiac  dysfunction
locke
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A unique acute cardiac attack called “takotsubo cardiomy-
pathy” or “transient left ventricular apical ballooning,” occurs
redominantly in postmenopausal women in association with
motional or physical stress [1–3]. The incidence of takotsubo car-
iomyopathy was also reported to increase just after the onset of
 major earthquake [4].  Emotional stress could induce myocardial
schemia by activation of the sympathetic nervous system [5–7].
oradrenaline and adrenaline could act directly on the heart via
peciﬁc cardiac adrenoceptors, increasing heart rate and myocar-
ial oxygen demand. The sympathetic nervous system could have
n impact on the heart by increasing systemic blood pressure and
ontraction of vascular smooth muscle cells.
Immobilization stress (IMO) is a popular method
f simulating emotional stress, which activates the
ypothalamic–pituitary–adrenocortical system and the sym-
athoadrenal system [8].  We  have succeeded in developing this
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model in rats [9–12]. Recently, we  reported the preventive mech-
anism of  and  adrenergic blockers on emotional stress-induced
cardiovascular response in rats [13,14].
Azelnidipine is a unique calcium blocker which does not
increase heart rate. The purpose of this study is to evaluate the effect
of azelnidipine to prevent emotional stress-induced cardiovascular
response in rats.
Materials and methods
Materials
Thirty-three male Sprague–Dawley rats (8–11 weeks-old) were
purchased from Japan SLC Inc. (Shizuoka, Japan) and housed in
a temperature-controlled environment. Experiments were per-
formed after allowing free access to food and water for 2 weeks.
Rats were restrained for 30 min  to reproduce emotional stress by
securing them on their back to a board using adhesive tape (immo-
bilization stress: IMO) in the same manner as previously reported
[9–14]. Rats were premedicated with azelnidipine (0.3 mg/kg),
labetalol (3 mg/kg), or vehicle, 120 min  before IMO. This study was
approved by the Osaka University Medical School Animal Care and
Use Committee and were in compliance the Osaka University Med-
ical School Guidelines for the Care and Use of Laboratory Animals.
vier Ltd. All rights reserved.
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Fig. 1. Protocol. Rats were restrained for 30 min  to reproduce emotional stress by securing them on their back to a board using adhesive tape. Rats were premedicated with
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entobarbital and fractional left ventricular area change, blood pressure (BP) and h
0  min.
stimation of cardiac function by echocardiography
Immediately after IMO  for 30 min, 17 rats were anesthetized
ith sodium pentobarbital (40 mg/kg, ip) (Fig. 1). Fractional left
entricular area change (FAC) was measured at the papillary muscle
evel as shown in Fig. 2 using SONOS5500 (Philips Medical Systems,
ndover, MA,  USA) with s12 probe (frequency: 5–12 MHz, frame
ate: >120 Hz) at the end of IMO  and every 10 min  under anesthesia
or 60 min.
emodynamic measurement
During IMO, we also measured systemic blood pressure from a
emoral artery and heart rate from electrocardiogram in 16 rats by
ocal anesthesia. Immediately after IMO  for 30 min, all rats were
nesthetized with sodium pentobarbital (40 mg/kg, ip) and we
easured systemic blood pressure and heart rate at every 10 min
nder anesthesia for 60 min.tatistical analysis
Data are shown as mean ± SD. Statistical analysis was performed
y two-way ANOVA followed by Fisher’s protected least signiﬁcant
ig. 2. Assessment of left ventricular contractility by 2-dimensional echocardiography. E
uscle levels as shown in A and B. Dotted lines indicate the endocardial margin. Fractionress (IMO). Immediately after IMO  for 30 min, rats were anesthetized with sodium
ate (HR) were measured at the end of IMO  and every 10 min  under anesthesia for
difference test, or Student’s t-test using JMP  software (SAS Campus,
Carey, NC, USA). Differences were considered signiﬁcant at p < 0.05.
Results
Left ventricular contraction
Left ventricle showed hypercontraction in the vehicle or azelni-
dipine group during IMO  stress (90 ± 5% and 93 ± 1%, respectively).
There was no signiﬁcant difference in FAC during IMO  in both
groups. FAC during IMO  stress in the labetalol group was signiﬁ-
cantly lower than FAC in the other groups (81 ± 2%, p < 0.05).
Just after induction of general anesthesia, left ventricular con-
traction was signiﬁcantly reduced in all three groups. Reduction in
FAC was most prominent at 10 or 20 min  after the induction of anes-
thesia. FAC at 20 min  in the vehicle group was signiﬁcantly lower
than FAC in the other two groups (56 ± 11% vs. 86 ± 9%, 73 ± 5%,
p < 0.05). FAC at 20 min  in the labetalol group was also signiﬁ-
cantly lower than FAC in the azelnidipine group. At 60 min after the
induction of anesthesia, FAC in the vehicle or azelnidipine group
recovered (90 ± 3% and 92 ± 1%). However, FAC at 60 min  in the
labetalol group did not (80 ± 2%) (Fig. 3).
nd diastolic area (EDA) and end systolic area (ESA) were measured at the papillary
al left ventricular area change (FAC) was deﬁned as indicated in the formula (C).
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Fig. 3. Time course of fractional left ventricular area change (FAC) after the end of immobilization stress (IMO) and induction to general anesthesia in vehicle, azelnidipine,
and  labetalol groups. FAC during IMO  stress in the labetalol group was signiﬁcantly lower than FAC in other groups (81 ± 2% vs. 90 ± 5%, 93 ± 1%, p < 0.05). FAC at 20 min in
the  vehicle group was  signiﬁcantly lower than FAC in the other two groups (56 ± 11% vs. 86 ± 9%, 73 ± 5%, p < 0.05). At 60 min  after the induction of anesthesia, FAC in the
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iehicle or azelnidipine group recovered (90 ± 3% and 92 ± 1%). However, FAC at 60 m
igniﬁcantly impaired in the vehicle and azelnidipine groups, however, FAC in the la
re  expressed as mean value ± SD.
In contrast, FAC without prior stress was not signiﬁcantly
mpaired in the vehicle and azelnidipine groups, however, FAC in
he labetalol group without prior stress was lower than FAC in the
ther two groups.
lood pressure and heart rate
Mean blood pressure in the azelnidipine and labetalol groups
uring IMO  stress was signiﬁcantly lower than that in the vehicle
roup (107 ± 5 mmHg, 106 ± 17 mmHg  vs. 124 ± 5 mmHg, p < 0.05)
Fig. 4). Just after induction of general anesthesia, mean blood pres-
ure in the three groups was signiﬁcantly reduced. Mean blood
ig. 4. Time course of mean blood pressure and heart rate after the end of immobilizatio
 labetalol group. Mean blood pressure in the azelnidipine and labetalol groups during 
06  ± 17 mmHg  vs. 124 ± 5 mmHg, p < 0.05). Heart rate during IMO stress in the labetalol g
86  ± 55 bpm). Just after induction of general anesthesia, heart rate in the three groups w
n  the other two  groups. The data are expressed as mean value ± SD. the labetalol group did not (80 ± 2%). In contrast, FAC without prior stress was not
ol group without prior stress was lower than FAC in the other two groups. The data
pressure in the azelnidipine and labetalol groups tended to be lower
than that in the vehicle group.
Heart rate during IMO  stress in the labetalol group was  lower
than that in the other two groups (453 ± 56 bpm vs. 507 ± 13 bpm,
486 ± 55 bpm). Just after induction of general anesthesia, heart rate
in the three groups was  signiﬁcantly reduced, but heart rate in the
labetalol group was lower than that in the other two  groups.
DiscussionThe present study demonstrated that azelnidipine attenuated
IMO-induced left ventricular systolic dysfunction like - and -
adrenergic blockers.
n stress (IMO) and induction to general anesthesia in a vehicle, an azelnidipine and
IMO  stress was signiﬁcantly lower than that in the vehicle group (107 ± 5 mmHg,
roup was lower than that in the other two groups (453 ± 56 bpm vs. 507 ± 13 bpm,
as signiﬁcantly reduced, but heart rate in the labetalol group was lower than that
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ffects of labetalol
Labetalol, an - and -adrenoceptor blocker, with a ratio
f 1–3, is effective not only in hypertension, but also in
ngina pectoris or mental stress [15]. Labetalol might prevent
MO-induced left ventricular systolic dysfunction to attenuate
ncreases of systemic blood pressure and heart rate during IMO.
athophysiological mechanisms of takotsubo cardiomyopathy are
till unknown. However, potential pathophysiological mecha-
isms include catecholamine-induced myocardial stunning or
yperkinesis of the basal left ventricular segments [16–18].  So
-adrenoceptor blockers are thought to be effective to prevent
atecholamine-induced myocardial stunning [19,20]. We  have pre-
iously reported that pretreatment with metoprolol suppressed
tress-induced tachycardia but not the elevation of the ST seg-
ent at the II, III, and aVF leads. In contrast, pretreatment with a
ombination of prazosin and metoprolol or amosulalol completely
bolished the stress-induced tachycardia and the elevation of the ST
egment [10]. These results indicate that inhibition of both 1- and
1-adrenoceptors is necessary for the inhibition of stress-induced
lectrocardiogram changes. Therefore, labetalol could be effective
o prevent IMO-induced left ventricular systolic dysfunction. In this
tudy, we could not evaluate the protective effect of azelnidipine
r labetalol on the elevation of the ST segment, because it was  very
ifﬁcult to evaluate cardiac function by echocardiography under
ttachment of electronic wire.
ffects of azelnidipine
Azelnidipine is a novel long-acting dihydropyridine-based cal-
ium blocker, which reduces blood pressure without increasing
he heart rate in patients with hypertension [21,22].  Konno et al.
eported that azelnidipine decreases an indicator of sympathetic
erve activity by an antioxidant effect mediated through inhibition
f nicotinamide adenine dinucleotide phosphate oxidase activity
nd activation of superoxide dismutase [23]. Azelnidipine could
igniﬁcantly attenuate increases of systemic blood pressure with-
ut increasing the heart rate during IMO  stress [24]. Reduction of
fterload by azelnidipine administration might be one mechanism
f prevention. Kain et al. reported that a cardioprotective effect of
zelnidipine might be, at least in part, due to its inhibitory ability
n free radical formation, or due to its free radical scavenging abil-
ty [25]. Furthermore, azelnidipine might be effective for takotsubo
ardiomyopathy to prevent coronary vasospasm.
In this study, we could not clarify which effect is important,
ympathoinhibitory or Ca-blocking effects of azelnidipine, because
e could not evaluate sympathoinhibitory or Ca-blocking effects
ndividually. So we need a further study to compare it with the
ffects of other Ca-blockers.
ffect of anesthesia
On the ﬁrst day, rats were anesthetized with sodium pentobar-
ital (40 mg/kg, ip) immediately after IMO  for 30 min  to exclude
entral nerve actions. Anesthetization with sodium pentobarbi-
al itself might reduce cardiac function. So we also measured
AC under anesthesia with sodium pentobarbital without prior
MO  on the day following IMO. FAC without prior stress was  not
igniﬁcantly impaired in the vehicle or azelnidipine groups, so
nesthetization with sodium pentobarbital did not have strong
ffects. However, FAC in the labetalol group without prior stress
as lower than FAC in the vehicle or azelnidipine groups. The
egative inotropic activity of labetalol might be augmented under
nesthetization.
[
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Study limitations
In this study, we  did not study responses at a molecular level. We
have already investigated and reported cardiac and vascular gene
proﬁles in response to IMO  in rats [13]. However, pathophysiolog-
ical mechanisms for takotsubo cardiomyopathy are still unknown.
We could not examine the dose response to IMO-induced
left ventricular systolic dysfunction. In this study, we examined
0.3 mg/kg of azelnidipine and 3 mg/kg of labetalol, which will be the
maximum clinical dose for a patient whose body weight is 50 kg.
Both 0.3 mg/kg of azelnidipine and 3 mg/kg of labetalol could be
effective to prevent IMO-induced left ventricular systolic dysfunc-
tion.
In this study, we studied the protective effect of azelnidipine
or a labetalol. We  could not evaluate the protective effect of other
anti-hypertensive drugs. We will try to study the protective effect
of other anti-hypertensive drugs to clarify protective mechanisms.
Clinical implications
The pathogenesis of takotsubo cardiomyopathy is yet to be
determined, while clinical observations strongly suggest that the
trigger of attack is emotional or physical stress and it predom-
inantly occurs in post-menopausal women. In this study, we
conﬁrmed, using animal models, that emotional stress induced left
ventricular dysfunction and azelnidipine administration partially
improved the contractility like the - and -blocker, labetalol.
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